A powerful artificial intelligence (AI) tool could give clinicians a head start in identifying life-threatening complications after stem cell and bone marrow transplants, according to new research from MUSC Hollings Cancer Center .
For many patients, a stem cell or bone marrow transplant is lifesaving. But recovery does not end when patients leave the hospital. For some, serious complications can emerge months later, often without warning.
One of the most challenging is chronic graft-versus-host disease (GVHD), a condition in which immune cells from the transplant attack a patient’s healthy tissues. The disease can affect multiple organs, including skin, eyes, mouth, joints and lungs, causing long-term disability or even death.
Now, researchers, led by Sophie Paczesny, M.D., Ph.D. , co-leader of the Cancer Biology and Immunology Research Program at Hollings, as well as Michael Martens, Ph.D., and Brent Logan, Ph.D., with the Center for International Blood and Marrow Transplant Research at the Medical College of Wisconsin, have developed an AI-based tool that may help clinicians to identify patients at higher risk for chronic GVHD before symptoms appear, opening the door to earlier monitoring.
Applying machine learning to immune-related proteins and validated clinical information, the team developed a tool – called BIOPREVENT – that estimates a patient’s future risk of developing chronic GVHD and dying from transplant-related causes. The study, published in the Journal of Clinical Investigation , combines immune biomarkers, clinical data and machine learning to create a tool for real-world risk prediction.
Despite major advances in transplant care, chronic GVHD remains one of the leading causes of illness and death after transplant. But the disease does not begin when symptoms appear; the biological changes that drive it start much earlier.
The first few months after a transplant are particularly critical. Patients may feel well, but immune activity beneath the surface can already be setting the stage for complications.
“By the time chronic GVHD is diagnosed, the disease process has often been unfolding for months, quietly hurting the body,” Paczesny said. “We wanted to know whether we could detect warning signs earlier, before patients feel sick, and soon enough for clinicians to intervene, before the damage becomes irreversible.”
To do so, the researchers analyzed data from 1,310 stem cell and bone marrow transplant recipients across four large, multicenter studies. Blood samples collected 90 to 100 days after transplant were tested for seven immune proteins linked to inflammation, immune activation and regulation, and tissue injury and remodeling. The immune biomarkers used in BIOPREVENT were identified and validated in an earlier study led by Paczesny.
Those biomarkers were combined with nine clinical factors, including patient age, transplant type, primary disease and prior complications, drawn from transplant registries. In the U.S., transplant centers are required to submit detailed, transplant-specific data to the Center for International Blood and Marrow Transplant Research, with additional review for clinical trial patients. According to Paczesny, that standardized information helped to ensure that the model was built on consistent, high-quality clinical data.
The team tested several machine-learning approaches to see whether they could predict patient outcomes more accurately than traditional statistical methods. The best-performing model, based on a statistical technique called Bayesian additive regression trees, became the foundation for BIOPREVENT.
The results showed that models combining blood biomarkers with clinical data consistently outperformed models based solely on clinical data, especially in predicting transplant-related mortality. The team further validated the tool in an independent group of transplant recipients, confirming that it reliably predicted risk beyond the patients used to build the model.
BIOPREVENT was also able to separate patients into low- and high-risk groups, with clear differences in their outcomes up to 18 months later. Notably, different biomarkers predicted different transplant outcomes, underscoring that chronic GVHD and transplant-related death are at least partially driven by distinct biological factors. For example, one blood biomarker was closely linked to the risk of death after transplant, while others were better at signaling who would later develop chronic GVHD.
To make the research usable beyond the study, the team developed BIOPREVENT into a free, web-based application. Clinicians can enter a patient’s clinical details and biomarker values and receive personalized risk estimates over time.
“It was important to us that this not remain a theoretical model or a tool limited to a single institution,” Paczesny said. “Making BIOPREVENT freely available helps ensure that researchers and clinicians can test it, learn from it and, ultimately, improve care for transplant patients.”
For now, BIOPREVENT is intended to support risk assessment and clinical research – not to guide treatment decisions. The next step, Paczesny said, will be conducting carefully designed clinical trials to test whether acting on these early risk signals, such as closer monitoring or preventive therapies for high-risk patients, can improve long-term outcomes.
More broadly, the study reflects a shift toward precision medicine in transplant care, using data to tailor follow-up to each patient’s individual risk.
“This isn’t about replacing clinical judgment,” Paczesny emphasized. “It’s about giving clinicians better information earlier so they can make more informed decisions.”
Although additional validation is needed before the tool can become part of routine care, the researchers believe that this approach represents an important step toward preventing one of transplant medicine’s most serious complications.
“For patients, the uncertainty after transplant can be incredibly stressful,” Paczesny said. “We hope that tools like BIOPREVENT can help us see what’s coming sooner and eventually lessen the toll of chronic GVHD.”
###
About MUSC Hollings Cancer Center
MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated cancer center with the largest academic-based cancer research program in the state. With more than 230 faculty cancer scientists from 20 academic departments, it has an annual research funding portfolio of more than $50 million and sponsors more than 200 clinical trials across the state. Hollings specialists include surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, psychologists and other clinical providers equipped to provide the full range of cancer care from diagnosis to survivorship. Hollings offers state-of-the-art cancer screenings, diagnostics, therapies and surgical techniques within its multidisciplinary clinics. Dedicated to preventing and reducing the cancer burden statewide, the Hollings Office of Community Outreach and Engagement works with community organizations to bring cancer education and prevention information to affected populations throughout the state. For more information, visit hollingscancercenter.musc.edu .
Journal of Clinical Investigation
Data/statistical analysis
People
The BIOPREVENT machine learning algorithm predicts chronic graft-versus-host disease and mortality risk using post-transplant biomarkers
16-Feb-2026